Avalon GloboCare Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US05344R2031
USD
1.46
0.13 (9.77%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

54.4 k

Shareholding (Mar 2025)

FII

0.12%

Held by 4 FIIs

DII

98.98%

Held by 1 DIIs

Promoter

0.00%

How big is Avalon GloboCare Corp.?

22-Jun-2025

As of Jun 18, Avalon GloboCare Corp. has a market capitalization of 6.47 million, with net sales of 1.38 million and a net profit of -9.01 million over the latest four quarters. Shareholder's funds are reported at 7.10 million, and total assets amount to 20.99 million.

As of Jun 18, Avalon GloboCare Corp. has a market capitalization of 6.47 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 1.38 million, while the sum of net profit for the same period is -9.01 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 7.10 million, and total assets amount to 20.99 million.

Read More

What does Avalon GloboCare Corp. do?

22-Jun-2025

Avalon GloboCare Corp. is a biotech developer and healthcare service provider in the Pharmaceuticals & Biotechnology industry, currently reporting net sales of $0 million and a net loss of $2 million as of March 2025, with a market cap of $6.47 million.

Overview: <BR>Avalon GloboCare Corp. is an intelligent biotech developer and healthcare service provider in the Pharmaceuticals & Biotechnology industry, operating within the micro-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 6.47 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.76 <BR>Return on Equity: 237.63% <BR>Price to Book: -1.66<BR><BR>Contact Details: <BR>Address: 4400 US Highway 9 Ste 3100, FREEHOLD NJ : 07728-4210 <BR>Tel: 1 646 7624517 <BR>Fax: 1 732 7805600 <BR>Website: http://www.avalon-globocare.com/

Read More

Should I buy, sell or hold Avalon GloboCare Corp.?

22-Jun-2025

Who are in the management team of Avalon GloboCare Corp.?

22-Jun-2025

As of March 2022, Avalon GloboCare Corp.'s management team includes Mr. Lu Wenzhao (Chairman), Dr. David Jin (CEO), and Ms. Li Meng (COO). The Board of Directors also features independent directors such as Mr. Wilbert Tauzin and Mr. Steven Sanders.

As of March 2022, the management team of Avalon GloboCare Corp. includes the following individuals:<BR><BR>- Mr. Lu Wenzhao, Chairman of the Board of Directors<BR>- Dr. David Jin, President, Chief Executive Officer, and Director<BR>- Ms. Li Meng, Chief Operating Officer, Secretary, and Director<BR><BR>Additionally, the Board of Directors features several independent directors: Mr. Wilbert Tauzin, Mr. Steven Sanders, Mr. William Stilley, Dr. Tevi Troy, and Mr. Lu Yancen.

Read More

Is Avalon GloboCare Corp. overvalued or undervalued?

20-Sep-2025

Avalon GloboCare Corp. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of -1.66, an EV to EBITDA ratio of -2.64, and a troubling ROCE of -180.71%, which positions it unfavorably compared to peers like CohBar, Inc. and Atreca, Inc.

As of 23 May 2017, Avalon GloboCare Corp. moved from a grade of does not qualify to risky. The company is overvalued given its negative financial metrics, including a Price to Book Value of -1.66 and an EV to EBITDA ratio of -2.64, indicating significant financial distress. Additionally, the Return on Capital Employed (ROCE) stands at a troubling -180.71%, further underscoring the company's challenges.<BR><BR>In comparison to its peers, Avalon GloboCare Corp. shows a less favorable position with a P/E ratio of -0.7611, while CohBar, Inc. holds a more attractive valuation with an EV to EBITDA of 0.8535. Atreca, Inc. is also in a precarious position with a P/E of -0.0467. Although specific return data is not available, the lack of positive performance metrics suggests that Avalon GloboCare Corp. is not keeping pace with broader market benchmarks like the S&P 500.

Read More

Is Avalon GloboCare Corp. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Avalon GloboCare Corp. is in a mildly bearish trend, with daily moving averages indicating bearishness, while weekly and monthly indicators show mixed signals.

As of 5 September 2025, the technical trend for Avalon GloboCare Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD and KST show mildly bullish signals. Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. The Dow Theory indicates a bearish trend on the monthly, with no trend on the weekly. There is no available return data to compare the company's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of -0.98% and Operating profit at 8.31% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.54
2

Flat results in Jun 25

3

Risky - Negative EBITDA

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.14

stock-summary
Return on Equity

167.00%

stock-summary
Price to Book

-1.27

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.47%
0%
-29.47%
6 Months
-58.29%
0%
-58.29%
1 Year
-38.66%
0%
-38.66%
2 Years
-80.57%
0%
-80.57%
3 Years
-97.37%
0%
-97.37%
4 Years
-98.97%
0%
-98.97%
5 Years
-99.2%
0%
-99.2%

Avalon GloboCare Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.98%
EBIT Growth (5y)
8.31%
EBIT to Interest (avg)
-8.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.76
Sales to Capital Employed (avg)
0.21
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.05%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.66
EV to EBIT
-2.50
EV to EBITDA
-2.64
EV to Capital Employed
4.51
EV to Sales
9.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-180.71%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.9%)

Foreign Institutions

Held by 4 Foreign Institutions (0.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 33.33% vs 0.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -440.00% vs 7.41% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.30",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.80",
          "val2": "-2.10",
          "chgp": "-80.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "0.60",
          "chgp": "83.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.50",
          "val2": "-0.10",
          "chgp": "-8,400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.50",
          "val2": "-2.50",
          "chgp": "-440.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11,095.70%",
          "val2": "-6,287.70%",
          "chgp": "-480.80%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 8.33% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 52.69% vs -40.34% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "1.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.80",
          "val2": "-6.90",
          "chgp": "44.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.40",
          "val2": "1.40",
          "chgp": "71.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.90",
          "val2": "-16.70",
          "chgp": "52.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,060.70%",
          "val2": "-5,719.60%",
          "chgp": "265.89%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.40
0.30
33.33%
Operating Profit (PBDIT) excl Other Income
-3.80
-2.10
-80.95%
Interest
1.10
0.60
83.33%
Exceptional Items
-8.50
-0.10
-8,400.00%
Consolidate Net Profit
-13.50
-2.50
-440.00%
Operating Profit Margin (Excl OI)
-11,095.70%
-6,287.70%
-480.80%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 33.33% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -440.00% vs 7.41% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1.30
1.30
Operating Profit (PBDIT) excl Other Income
-3.80
-6.90
44.93%
Interest
2.40
1.40
71.43%
Exceptional Items
0.40
0.40
Consolidate Net Profit
-7.90
-16.70
52.69%
Operating Profit Margin (Excl OI)
-3,060.70%
-5,719.60%
265.89%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 8.33% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 52.69% vs -40.34% in Dec 2023

stock-summaryCompany CV
About Avalon GloboCare Corp. stock-summary
stock-summary
Avalon GloboCare Corp.
Pharmaceuticals & Biotechnology
Avalon GloboCare Corp. is an intelligent biotech developer and healthcare service provider. The Company engages in the management of stem cell banks and specialty clinical laboratories. It is developing of exosome technology to improve the diagnosis and management of diseases. The Company operates through two platforms, Avalon Cell and Avalon Rehab. Its technology and service ecosystem covers the areas of regenerative medicine, cell-based immunotherapy, exosome technology, as well as rehabilitation medicine. The Company also focused on diagnostic advancements in the fields of oncology, infectious diseases and fibrotic diseases, and the discovery of disease-specific exosomes to provide the disease origin insight necessary to enable.
Company Coordinates stock-summary
Company Details
4400 US Highway 9 Ste 3100 , FREEHOLD NJ : 07728-4210
Registrar Details